NCT02756793

Stereotactic Radiotherapy for Oligo-Progressive Metastatic Cancer (The STOP Trial)

Stereotactic Radiotherapy for Oligo-Progressive Metastatic Cancer (The STOP Trial): A Randomized Phase II Trial

• Status: Active Not Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 90 (actual)
• Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A multicenter randomized phase II trial of stereotactic body radiotherapy for oligo-progressive metastatic cancers. Eligible patients will be randomized in a 1:2 ratio between receiving their standard of care therapy or stereotactic ablative radiotherapy (SABR) to all sites of oligo-progressive lesions.Radiotherapy will be administered as soon as possible following randomization, and subjects will be followed until next disease progression. The primary outcome is progression-free survival (PFS).

Conditions

• Metastatic Cancer

Interventions

Type	Name	Description
RADIATION	Stereotactic Ablative Radiotherapy (SABR)	Patients will receive stereotactic ablative radiotherapy to all sites of progressive disease, with continuation of current systemic agents.
OTHER	Standard of Care Treatment	May include: * Continue with current systemic agent(s) * Observation * Switch to next-line treatment Palliative radiotherapy is allowed in this arm.

Timeline

• Start date: 2016-10-01
• Primary completion: 2022-07-31
• Completion: 2026-06-01
• First posted: 2016-04-29
• Last updated: 2025-12-31

Locations

7 sites across 1 country: Canada